Johnson & Johnson seeks permission to conduct phase 3 trials for single-shot vaccine in India
The company sought an early meeting of the subject expert committee of the CDSCO to take a decision on its application, sources told PTI
New Delhi: Multinational pharma giant Johnson & Johnson has applied to India's drug regulator seeking permission to conduct phase-3 clinical trial of its single-dose COVID-19 vaccine in India as well as import licence, sources said.
They said the company has sought an early meeting of the subject expert committee on COVID-19 of the Central Drugs Standard Control Organisation (CDSCO) to take a decision on its application.
This comes close to the heels of the central government last week deciding to fast-track emergency approvals for all foreign produced coronavirus jabs that have been given a similar nod by the World Health Organization or regulators in the United States, Europe, Britain or Japan.
Such vaccines will be given emergency use approval mandating the requirement of post-approval parallel bridging clinical trial in place of conduct of local clinical trial under the provisions of the New Drugs and Clinical Trials Rules 2019, the health ministry had said.
According to sources, Johnson & Johnson had applied on 12 April in the Global Clinical Trial Division through the Sugam online portal, instead of applying to the biological division which deals with vaccines and other biologicals.
"Due to the technicalities involved, Johnson & Johnson has resubmitted its application on Monday," a source said.
The J&J vaccine can be stored for up to three months in a temperature between 2 and 8 degrees Celsius.
Johnson & Johnson's vaccine is a single-dose jab, whereas the three vaccines cleared by India so far are of doubles doses.
So far, two vaccines — Oxford/Astrazeneca vaccine COVISHIELD manufactured by Serum Institute in India and indigenously developed COVAXIN by Bharat Biotech — are being administered in India, while a third vaccine Sputnik V, developed in Russia and to be imported and sold in India by Dr Reddy's Laboratories, has also been approved by the Indian drug regulator.
The government, meanwhile, on Monday decided to expand its vaccination drive by allowing everyone above18 years of age eligible to be vaccinated from May 1 and permitted state governments, private hospitals and industrial establishments to procure the doses directly from manufacturers.
The active cases comprise 0.05 per cent of the total infections, while the national COVID-19 recovery rate was recorded at 98.74 per cent, the ministry said.
So far, more than 3.01 crore (3,01,97,120) children in the age group of 12-14 years have been administered the first dose of COVID-19 vaccine.
India's COVID-19 daily case positivity rate has now dropped to 0.47 per cent as compared to 0.95 per cent reported a day ago. The weekly positivity rate is currently at 0.79 per cent